Abstract
Peptide receptor radionuclide therapy (PRRT) is a molecular-targeted therapy in which a somatostatin analogue (a small peptide) is coupled with a radioligand so that the radiation dose is selectively administered to somatostatin receptor-expressing metastasized neuroendocrine tumors, particularly gastroenteropancreatic. Reported toxicities include myelotoxicity and nephrotoxicity, the latter manifesting as decreased kidney function, often developing months to years after treatment completion. We present a case of PRRT-induced kidney toxicity manifesting as a severe Gitelman-like tubulopathy with preserved kidney function. Because profound hypokalemia and hypocalcemia can lead to life-threatening arrhythmias, we highlight the necessity for careful monitoring of serum and urine electrolytes in patients receiving PRRT.
Original language | English |
---|---|
Journal | American Journal of Kidney Diseases |
DOIs | |
Publication status | Accepted/In press - 2017 |
Keywords
- 177-Lu-DOTATATE
- Cancer
- Case report
- Gitelman
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Nephrotoxicity
- Neuroendocrine tumors (NETs)
- Peptide receptor radionuclide therapy (PRRT)
- Radiometabolic
- Tubulopathy
- Urine electrolytes
ASJC Scopus subject areas
- Nephrology